Edwin M. Spithoven

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

Edwin M. Spithoven, Anneke Kramer, Esther Meijer et al. · Nephrology Dialysis Transplantation · 2014 · 237 citations · Full text

Medicine, Internal Medicine, Nephrology +10

Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

Edwin M. Spithoven, Anneke Kramer, Esther Meijer et al. · Kidney International · 2014 · 123 citations · Full text

Medicine, Internal Medicine, Nephrology +6

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Folkert W. Visser, R. Aerts et al. · JAMA · 2018 · 107 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

R. Aerts, Wietske Kievit, Hedwig M. A. D‘Agnolo et al. · Gastroenterology · 2019 · 83 citations · Full text

Medicine, Genetics, Internal Medicine +12

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Esther Meijer, Joost P.H. Drenth, Hedwig M. A. D‘Agnolo et al. · American Journal of Kidney Diseases · 2013 · 70 citations · Full text

Medicine, Nephrology, Pharmacotherapy +9